HTG Molecular Diagnostics (NASDAQ:HTGM) reported Q2 EPS of ($0.54), $0.11 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $2.35 million.
HTG Molecular Diagnostics (NASDAQ:HTGM) reported Q2 EPS of ($0.54), $0.11 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $2.35 million.